<DOC>
	<DOC>NCT02515747</DOC>
	<brief_summary>The purpose of this study is to explore the role of lipoprotein(a) and apolipoprotein(a) phenotype in fatal and non-fatal cardiovascular disease (CVD) events risk in coronary disease patients divided on the basis of management strategy - medical, endovascular or open cardiac surgery.</brief_summary>
	<brief_title>Prospective Russian Evaluation of Lp(a) Role in cardiovascUlar DiseasE</brief_title>
	<detailed_description>Between January 1993 and September 2006, we enrolled 1400 consecutive patients from the Atherosclerosis Department with known Lp(a) levels and coronary heart disease (CHD) verified by angiography. In accordance with clinical condition and angiography data were assigned them into three parallel treatment arms and followed up to 15 years. This study was conducted according to the principles of the Declaration of Helsinki and the Institutional Ethics Committee.</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>stable coronary heart disease verified by angiography acute coronary syndromes, acute infections, inflammatory disease within 3 months prior to inclusion, familial hypercholesterolemia, triglycerides&gt;4.5 mmol/L, missing Lp(a) measurements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Lipoprotein(a)</keyword>
	<keyword>coronary artery bypass grafting (CABG)</keyword>
	<keyword>apo(a)</keyword>
	<keyword>prognosis</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>cardiovascular death</keyword>
	<keyword>percutaneous coronary intervention (PCI)</keyword>
</DOC>